1,503
Views
13
CrossRef citations to date
0
Altmetric
Review

Germline Genetic Profiling in Prostate Cancer: Latest Developments and Potential Clinical Applications

&
Article: FSO87 | Received 20 Apr 2015, Accepted 10 Nov 2015, Published online: 18 Dec 2015

Figures & data

Figure 1. Diagram above showing that prostate cancer susceptibility is likely to be due to a mixed model of common and rare variants [Citation83].

Permission obtained from Nature Publishing Groups.

Figure 1.  Diagram above showing that prostate cancer susceptibility is likely to be due to a mixed model of common and rare variants [Citation83].Permission obtained from Nature Publishing Groups.

Figure 2. Showing members of the consortia who are involved with investigating the role of genetic variants of prostate cancer.

It highlights the collaborative efforts needed to answer the various scientific and clinical questions.

BPC3:Breast Prostate Cancer Cohort Consortium [Citation139]; CAPS: Cancer in the Prostate in Sweden [Citation140]; CGEMS: The Cancer Marker Susceptibility Projects [Citation141]; ELLIPSE: Elucidating Loci Involved in Prostate Cancer [Citation142]; GWAS: Genome Wide Association Studies; GENPET: An imaging study of FCH-PET-CT in men with prostate cancer and a BRCA gene mutation (Study in preparation) (Research Ethics Number: 15/20/0242); GENPROS: Analysing outcomes after prostate cancer diagnosis and treatment in carriers of rare germline mutation in cancer predisposition genes. (Study in preparation) (Research Ethics Number: 14/20/0072); ICPCG: International Consortium of Prostate Cancer Genetics [Citation143]; IMPACT: The Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted Screening in BRCA1/BRCA2 mutation carriers and controls [Citation144]; MADCaP: Men of African Decent and Prostate Cancer [Citation145]; PRACTICAL: Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome [Citation146]; PROFILE: Germline genetic profiling: Correlation with targeted prostate cancer screening and treatment [Citation147].

Figure 2.  Showing members of the consortia who are involved with investigating the role of genetic variants of prostate cancer.It highlights the collaborative efforts needed to answer the various scientific and clinical questions.BPC3:Breast Prostate Cancer Cohort Consortium [Citation139]; CAPS: Cancer in the Prostate in Sweden [Citation140]; CGEMS: The Cancer Marker Susceptibility Projects [Citation141]; ELLIPSE: Elucidating Loci Involved in Prostate Cancer [Citation142]; GWAS: Genome Wide Association Studies; GENPET: An imaging study of FCH-PET-CT in men with prostate cancer and a BRCA gene mutation (Study in preparation) (Research Ethics Number: 15/20/0242); GENPROS: Analysing outcomes after prostate cancer diagnosis and treatment in carriers of rare germline mutation in cancer predisposition genes. (Study in preparation) (Research Ethics Number: 14/20/0072); ICPCG: International Consortium of Prostate Cancer Genetics [Citation143]; IMPACT: The Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted Screening in BRCA1/BRCA2 mutation carriers and controls [Citation144]; MADCaP: Men of African Decent and Prostate Cancer [Citation145]; PRACTICAL: Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome [Citation146]; PROFILE: Germline genetic profiling: Correlation with targeted prostate cancer screening and treatment [Citation147].
Supplemental material

Supplementary Table 1-Showing common susceptibility loci identified in GWAS and recent meta-analysis.

Download MS Word (374.6 KB)